Switch theme
Sign up to access all valuation multiples
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
2014
166
LTM Revenue $39.5M
LTM EBITDA -$192M
-$206M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Zentalis Pharma has a last 12-month revenue (LTM) of $39.5M and a last 12-month EBITDA of -$192M.
In the most recent fiscal year, Zentalis Pharma achieved revenue of $67.4M and an EBITDA of -$186M.
Zentalis Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Zentalis Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $39.5M | XXX | $67.4M | XXX | XXX | XXX |
| Gross Profit | $39.5M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$192M | XXX | -$186M | XXX | XXX | XXX |
| EBITDA Margin | -485% | XXX | -276% | XXX | XXX | XXX |
| EBIT | -$183M | XXX | -$187M | XXX | XXX | XXX |
| EBIT Margin | -463% | XXX | -278% | XXX | XXX | XXX |
| Net Profit | -$165M | XXX | -$166M | XXX | XXX | XXX |
| Net Margin | -418% | XXX | -246% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Zentalis Pharma's stock price is $1.
Zentalis Pharma has current market cap of $87.4M, and EV of -$206M.
See Zentalis Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$206M | $87.4M | XXX | XXX | XXX | XXX | $-2.29 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Zentalis Pharma has market cap of $87.4M and EV of -$206M.
Zentalis Pharma's trades at -3.1x EV/Revenue multiple, and 1.1x EV/EBITDA.
Equity research analysts estimate Zentalis Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zentalis Pharma has a P/E ratio of -0.5x.
See valuation multiples for Zentalis Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $87.4M | XXX | $87.4M | XXX | XXX | XXX |
| EV (current) | -$206M | XXX | -$206M | XXX | XXX | XXX |
| EV/Revenue | -5.2x | XXX | -3.1x | XXX | XXX | XXX |
| EV/EBITDA | 1.1x | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBIT | 1.1x | XXX | 1.1x | XXX | XXX | XXX |
| EV/Gross Profit | -5.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.5x | XXX | -0.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 1.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialZentalis Pharma's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $1.5M for the same period.
Zentalis Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Zentalis Pharma's rule of X is -485% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Zentalis Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -485% | XXX | -276% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | -12% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -485% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 249% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 378% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zentalis Pharma acquired XXX companies to date.
Last acquisition by Zentalis Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Zentalis Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Zentalis Pharma founded? | Zentalis Pharma was founded in 2014. |
| Where is Zentalis Pharma headquartered? | Zentalis Pharma is headquartered in United States of America. |
| How many employees does Zentalis Pharma have? | As of today, Zentalis Pharma has 166 employees. |
| Who is the CEO of Zentalis Pharma? | Zentalis Pharma's CEO is Ms. Julie M. Eastland. |
| Is Zentalis Pharma publicy listed? | Yes, Zentalis Pharma is a public company listed on NAS. |
| What is the stock symbol of Zentalis Pharma? | Zentalis Pharma trades under ZNTL ticker. |
| When did Zentalis Pharma go public? | Zentalis Pharma went public in 2020. |
| Who are competitors of Zentalis Pharma? | Similar companies to Zentalis Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Zentalis Pharma? | Zentalis Pharma's current market cap is $87.4M |
| What is the current revenue of Zentalis Pharma? | Zentalis Pharma's last 12 months revenue is $39.5M. |
| What is the current EV/Revenue multiple of Zentalis Pharma? | Current revenue multiple of Zentalis Pharma is -5.2x. |
| Is Zentalis Pharma profitable? | Yes, Zentalis Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Zentalis Pharma? | Zentalis Pharma's last 12 months EBITDA is -$192M. |
| What is Zentalis Pharma's EBITDA margin? | Zentalis Pharma's last 12 months EBITDA margin is -485%. |
| What is the current EV/EBITDA multiple of Zentalis Pharma? | Current EBITDA multiple of Zentalis Pharma is 1.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
